US class II risk for PE (Perkin Elmer) newborn test:
This article was originally published in Clinica
Executive Summary
The US FDA has finalised plans to classify a newborn screening test manufactured by Perkin Elmer (PE) as a class II (medium-risk) device. The company petitioned for a change in classification for its NeoGram Amino Acids and Acylcarnitines Tandem Mass Spectrometry Kit after the agency concluded that the test was a de novo device with no predicate, requiring the initial class III (high-risk) category. The product can now be cleared via the 510(k) process provided it meets the guidance document requirements on validation of performance characteristics and labelling developed by the agency, the FDA said.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.